What is Taysha Gene Therapies, Inc. Common Stock's Market Cap?

Taysha Gene Therapies, Inc. Common Stock's Market Cap is $1.8B, based on as-reported figures from SEC (XBRL) filings.

What is Taysha Gene Therapies, Inc. Common Stock's Enterprise Value?

Taysha Gene Therapies, Inc. Common Stock's Enterprise Value is $1.4B, based on as-reported figures from SEC (XBRL) filings.

What is Taysha Gene Therapies, Inc. Common Stock's Price / Sales?

Taysha Gene Therapies, Inc. Common Stock's Price / Sales is 325.5×, based on as-reported figures from SEC (XBRL) filings.

What is Taysha Gene Therapies, Inc. Common Stock's EV / Revenue?

Taysha Gene Therapies, Inc. Common Stock's EV / Revenue is 251.5×, based on as-reported figures from SEC (XBRL) filings.

What is Taysha Gene Therapies, Inc. Common Stock's EV / EBITDA?

Taysha Gene Therapies, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Taysha Gene Therapies, Inc. Common Stock's Revenue (TTM)?

Taysha Gene Therapies, Inc. Common Stock's Revenue (TTM) is $5.5M, based on as-reported figures from SEC (XBRL) filings.

What is Taysha Gene Therapies, Inc. Common Stock's Net Income (TTM)?

Taysha Gene Therapies, Inc. Common Stock's Net Income (TTM) is -$149.6M, based on as-reported figures from SEC (XBRL) filings.

What is Taysha Gene Therapies, Inc. Common Stock's EBITDA?

Taysha Gene Therapies, Inc. Common Stock's EBITDA is -$152.0M, based on as-reported figures from SEC (XBRL) filings.

What is Taysha Gene Therapies, Inc. Common Stock's Diluted EPS (TTM)?

Taysha Gene Therapies, Inc. Common Stock's Diluted EPS (TTM) is -0.46, based on as-reported figures from SEC (XBRL) filings.

What is Taysha Gene Therapies, Inc. Common Stock's EBITDA Margin?

Taysha Gene Therapies, Inc. Common Stock's EBITDA Margin is -2771.0%, based on as-reported figures from SEC (XBRL) filings.

Taysha Gene Therapies, Inc. Common Stock (TSHA) Financial Statements

Taysha Gene Therapies, Inc. Common Stock

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG00TJXFDQ0

XNAS · usd

5.48▼ 0.12 (-2.14%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close5.60

Day's Range5.40 – 5.58

52-Week Range2.71 – 7.30

Volume1.5M

Avg Volume2.3M

Share Statistics

Shares Outstanding

Employees99

ExchangeXNAS

Listed2020-09-24

Share count as of August 11, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Taysha Gene Therapies, Inc. Common Stock (TSHA)

What is Taysha Gene Therapies, Inc. Common Stock's Market Cap?: Taysha Gene Therapies, Inc. Common Stock's Market Cap is $1.8B, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's Enterprise Value?: Taysha Gene Therapies, Inc. Common Stock's Enterprise Value is $1.4B, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's Price / Sales?: Taysha Gene Therapies, Inc. Common Stock's Price / Sales is 325.5×, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's EV / Revenue?: Taysha Gene Therapies, Inc. Common Stock's EV / Revenue is 251.5×, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's EV / EBITDA?: Taysha Gene Therapies, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's Revenue (TTM)?: Taysha Gene Therapies, Inc. Common Stock's Revenue (TTM) is $5.5M, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's Net Income (TTM)?: Taysha Gene Therapies, Inc. Common Stock's Net Income (TTM) is -$149.6M, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's EBITDA?: Taysha Gene Therapies, Inc. Common Stock's EBITDA is -$152.0M, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's Diluted EPS (TTM)?: Taysha Gene Therapies, Inc. Common Stock's Diluted EPS (TTM) is -0.46, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's EBITDA Margin?: Taysha Gene Therapies, Inc. Common Stock's EBITDA Margin is -2771.0%, based on as-reported figures from SEC (XBRL) filings.